Skip to main content
. 2010 Oct 18;120(11):3843–3854. doi: 10.1172/JCI42059

Figure 2. Association between NOS2 expression and breast cancer survival by ER status.

Figure 2

(A) Kaplan-Meier cumulative breast cancer–specific survival curves of ER-negative breast cancer patients by NOS2 status (n = 98). The survival of patients with high NOS2 expression (n = 71) was significantly poorer than the survival of patients with low NOS2 expression (n = 27). P < 0.001, log-rank test. (B) ER-positive breast cancer patients by NOS2 status (n = 139). The survival of patients with high NOS2 expression (n = 95) was not significantly different from the survival of patients with low NOS2 expression (n = 44). P = 0.315. (C) Basal-like breast cancer (ER–/HER2–, and EGFR- or cytokeratin5/6-positive) by NOS2 status (n = 41). The survival of patients with high NOS2 expression (n = 29) was significantly poorer than the survival of patients with low NOS2 expression (n = 12). P = 0.038.